Imagine a world where a simple blood test could predict your risk of developing Alzheimer's disease. Sounds like a game-changer, right? But here's the catch: it's not as straightforward as it seems. A recent study presented at the NSGC Annual Conference in 2025 has shed light on the intricate nature of Alzheimer's risk assessment and the crucial role genetic counselors play in interpreting these complex results.
The study focused on individuals with a specific genetic makeup, known as APOE ϵ4/ϵ4 carriers. These individuals were found to be at a significantly higher risk of developing mild cognitive impairment or Alzheimer's disease-associated dementia, based on their biomarker test results. However, and here's where it gets controversial, a significant number of individuals without this particular genetic profile also showed evidence of Alzheimer's pathology in their biomarker tests.
Lead author Matt Tschirgi, from Quest Diagnostics, presented these findings at the conference, highlighting the complexity of interpreting such results. Among the 21,267 individuals who underwent beta-amyloid testing, a substantial 27.1% were classified as higher risk, similar to previous studies. But here's the twist: there was no significant difference observed between individuals with different APOE ε3 and ε4 homozygous statuses.
The study also looked at p-tau 181 and p-tau 217 testing, which revealed that a significant proportion of individuals, regardless of their APOE status, had results consistent with mild cognitive impairment or dementia. This finding challenges the notion that APOE ϵ4/ϵ4 is the sole indicator of Alzheimer's risk.
So, what does this mean for genetic counselors and the role they play in testing and counseling individuals? Certified genetic counselors, with their expertise, can help interpret these complex and sometimes conflicting results, supporting informed decision-making. As more therapies for Alzheimer's become available, their role becomes even more critical.
The growing focus on Alzheimer's disease, driven by emerging therapies, biomarker testing, and recent publications, has sparked discussions about the role of genetic counselors. While APOE allele status remains the strongest known genetic risk factor for late-onset Alzheimer's, newer blood biomarker assays add a layer of complexity to counseling discussions.
So, is APOE ϵ4/ϵ4 the sole predictor of Alzheimer's risk? Or are there other factors at play? These questions highlight the need for further research and discussion. What are your thoughts? Do you think genetic counselors play a vital role in interpreting these complex results? Share your thoughts in the comments below!
